Search

Your search keyword '"Fanti, S"' showing total 1,851 results
Start Over Author "Fanti, S"
1,851 results on '"Fanti, S"'

3. Teaching Cases in Nuclear Oncology: Pancreatic Cancer

Author

Lorenzoni, Alice, primary, Alessi, Alessandra, additional, Crippa, Flavio, additional, Tabacchi, E., additional, Nanni, C., additional, Bossert, I., additional, Maffione, A. M., additional, Fanti, S., additional, Olivari, L., additional, and Chiti, A., additional

Published
2022
Full Text
View/download PDF

4. PSMA-PET vs. conventional imaging for preoperative staging high-risk PCa patients underwent surgery for cN0M0 disease

Author

Bianchi, L., primary, Valerio, M., additional, Novello, Q., additional, Balestrazzi, E., additional, Bevilacqua, F., additional, Nanni, L., additional, Droghetti, M., additional, Piazza, P., additional, Gandaglia, G., additional, Ceci, F., additional, Farolfi, A., additional, Fanti, S., additional, Briganti, A., additional, Montorsi, F., additional, Schiavina, R., additional, and Brunocilla, E., additional

Published
2024
Full Text
View/download PDF

7. Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients

Author

Eertink, J.J., Burggraaff, C.N., Heymans, M.W., Dührsen, U., Hüttmann, A., Schmitz, C., Müller, S., Lugtenburg, P.J., Barrington, S.F., Mikhaeel, N.G., Carr, R., Czibor, S., Györke, T., Ceriani, L., Zucca, E., Hutchings, M., Kostakoglu, L., Loft, A., Fanti, S., Wiegers, S.E., Pieplenbosch, S., Boellaard, R., Hoekstra, O.S., Zijlstra, J.M., and de Vet, H.C.W.

Published
2021
Full Text
View/download PDF

9. Off-Label Use of Letermovir as Preemptive Anti-Cytomegalovirus Therapy in a Pediatric Allogeneic Peripheral Blood Stem Cell Transplant

Author

Chiereghin A, Belotti T, Borgatti EC, Fraccascia N, Piccirilli G, Fois M, Borghi M, Turello G, Gabrielli L, Masetti R, Prete A, Fanti S, and Lazzarotto T

Subjects
pediatric allogeneic peripheral blood stem cell transplant, gcv-resistant cmv, intolerance to fos, off-label letermovir use., Infectious and parasitic diseases, RC109-216
Abstract

Angela Chiereghin,1,2 Tamara Belotti,3 Eva Caterina Borgatti,4 Nicola Fraccascia,5 Giulia Piccirilli,6 Maura Fois,3 Michele Borghi,4 Gabriele Turello,4 Liliana Gabrielli,6 Riccardo Masetti,3 Arcangelo Prete,3 Stefano Fanti,5 Tiziana Lazzarotto4 1Section of Microbiology, Department of Specialized, Experimental, and Diagnostic Medicine, University of Bologna, Bologna, Italy; 2Department of Public Health, Local Health Authority of Bologna, Bologna, Italy; 3Pediatric Oncology and Haematology Unit “Lalla Seragnoli”, Department of Pediatrics, IRCCS St. Orsola Polyclinic, University of Bologna, Bologna, Italy; 4Microbiology Unit, Department of Specialized, Experimental, and Diagnostic Medicine, IRCCS St. Orsola Polyclinic, University of Bologna, Bologna, Italy; 5Nuclear Medicine Unit, Department of Specialized, Experimental, and Diagnostic Medicine, IRCCS St. Orsola Polyclinic, University of Bologna, Bologna, Italy; 6Microbiology Unit, IRCCS St. Orsola Polyclinic, University of Bologna, Bologna, ItalyCorrespondence: Tiziana LazzarottoMicrobiology Unit, Department of Specialized, Experimental, and Diagnostic Medicine, IRCCS St. Orsola Polyclinic, University of Bologna, via Massarenti 9, Bologna, 40138, ItalyTel +39 0512143360Fax +39 0512143514Email tiziana.lazzarotto@unibo.itAbstract: Despite the effectiveness of the currently available antiviral drugs in treating cytomegalovirus (CMV) infection, high rates of adverse effects are associated with their use. Moreover, a problem of increasing importance is the emergence of drug-resistant CMV infection. Here, we describe the first case of off-label use of letermovir (LMV) as preemptive antiviral therapy, in a pediatric allogeneic peripheral blood stem cell transplant recipient with ganciclovir-resistant CMV infection who was intolerant to foscarnet and unable to achieve viral clearance after seven doses of cidofovir. After the administration of LMV, a gradual reduction in viral load was observed and within 6 weeks of LMV treatment, after more than 6 months of positive CMV-DNAemia, the patient cleared the infection. No adverse effects associated with LMV were observed during treatment. In this pediatric study case, the off-label use of LMV for the treatment of CMV infection has been well tolerated and proved to be effective in leading to the suppression of viral replication.Keywords: pediatric allogeneic peripheral blood stem cell transplant, GCV-resistant CMV, intolerance to FOS, off-label letermovir use

Published
2021

11. Second line PSMA-targeted salvage treatment in patients with mi N1/M1a-b oligorecurrent PCa

Author

Bianchi, L., primary, Balestrazzi, E., additional, Ceci, F., additional, Costa, F., additional, Droghetti, M., additional, Pissavini, P., additional, Piazza, P., additional, Tamburini, S., additional, Monti, M., additional, Farolfi, A., additional, Mei, R., additional, Castellucci, P., additional, Puliatti, S., additional, Gandaglia, G., additional, Larcher, A., additional, Mottrie, A., additional, Briganti, A., additional, Morganti, A.G., additional, Fanti, S., additional, Montorsi, F., additional, Schiavina, R., additional, and Brunocilla, E., additional

Published
2023
Full Text
View/download PDF

14. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

Author

Horwich, A., Babjuk, M., Bellmunt, J., Bruins, H.M., De Reijke, T.M., De Santis, M., Gillessen, S., James, N., Maclennan, S., Palou, J., Powles, T., Ribal, M.J., Shariat, S.F., Van Der Kwast, T., Xylinas, E., Agarwal, N., Arends, T., Bamias, A., Birtle, A., Black, P.C., Bochner, B.H., Bolla, M., Boormans, J.L., Bossi, A., Briganti, A., Brummelhuis, I., Burger, M., Castellano, D., Cathomas, R., Chiti, A., Choudhury, A., Compérat, E., Crabb, S., Culine, S., De Bari, B., DeBlok, W., De Visschere, P.J.L., Decaestecker, K., Dimitropoulos, K., Dominguez-Escrig, J.L., Fanti, S., Fonteyne, V., Frydenberg, M., Futterer, J.J., Gakis, G., Geavlete, B., Gontero, P., Grubmüller, B., Hafeez, S., Hansel, D.E., Hartmann, A., Hayne, D., Henry, A.M., Hernandez, V., Herr, H., Herrmann, K., Hoskin, P., Huguet, J., Jereczek-Fossa, B.A., Jones, R., Kamat, A.M., Khoo, V., Kiltie, A.E., Krege, S., Ladoire, S., Lara, P.C., Leliveld, A., Linares-Espinós, E., Løgager, V., Lorch, A., Loriot, Y., Meijer, R., Carmen Mir, M., Moschini, M., Mostafid, H., Müller, A.-C., Müller, C.R., N’Dow, J., Necchi, A., Neuzillet, Y., Oddens, J.R., Oldenburg, J., Osanto, S., Oyen, W.J.G., Pacheco-Figueiredo, L., Pappot, H., Patel, M.I., Pieters, B.R., Plass, K., Remzi, M., Retz, M., Richenberg, J., Rink, M., Roghmann, F., Rosenberg, J.E., Rouprêt, M., Rouvière, O., Salembier, C., Salminen, A., Sargos, P., Sengupta, S., Sherif, A., Smeenk, R.J., Smits, A., Stenzl, A., Thalmann, G.N., Tombal, B., Turkbey, B., Vahr Lauridsen, S., Valdagni, R., Van Der Heijden, A.G., Van Poppel, H., Vartolomei, M.D., Veskimäe, E., Vilaseca, A., Vives Rivera, F.A., Wiegel, T., Wiklund, P., Williams, A., Zigeuner, R., and Witjes, J.A.

Published
2019
Full Text
View/download PDF

19. Radiologically defined lipid-poor adrenal adenomas: histopathological characteristics

Author

De Leo, A., Mosconi, C., Zavatta, G., Tucci, L., Nanni, C., Selva, S., Balacchi, C., Ceccarelli, C., Santini, D., Pantaleo, M. A., Minni, F., Fanti, S., Golfieri, R., Pagotto, U., Vicennati, V., and Di Dalmazi, G.

Abstract

Background: Adrenal lipid-poor adenomas (LPA) are defined by high unenhanced density (≥ 10 HU), and absolute and relative contrast medium washout > 60% and > 40%, respectively, at computerized tomography (CT). To date, no thorough histopathological characterization has been performed in those frequent lesions (one-third of adrenal adenomas). Our aim was to analyze the histopathological characteristics of adrenal LPA. Methods: Patients with LPA (n= 57) were selected among consecutive subjects referred for an adrenal incidentaloma or ACTH-independent Cushing syndrome. FluoroDeoxyGlucose-Positron Emission Tomography (FDG-PET) was performed in 37 patients. In patients treated by adrenalectomy (n= 17), Weiss score and Lin–Weiss–Bisceglia score (in tumors composed entirely or predominantly of oncocytes) were calculated. Results: Radiological parameters did not differ among patients with ACTH-independent Cushing syndrome (n= 6) and those with adrenal incidentalomas associated with primary aldosteronism (n= 2), autonomous cortisol secretion (n= 14), or non-functioning (n= 35). Patients treated by adrenalectomy had larger tumors (28.9 ± 11.2 vs17.3 ± 8.4 mm,P< 0.001), higher CT unenhanced density (29.1 ± 11.0 vs23.1 ± 9.0 HU, P= 0.043), and FDG-PET adrenal uptake (9.0 ± 6.4 vs4.4 ± 2.3 SUV, P= 0.003) than non-operated ones. Oncocytic features > 75% of the tumor were detected in 12/17 cases (70.6%). Five of those showed borderline-malignant histopathological characteristics by Lin–Weiss–Bisceglia score. Among remaining non-oncocytic tumors, 1/5 had a Weiss score ≥ 3. Overall, 6/17 tumors (35.3%) had borderline-malignant potential. Radiological parameters were similar between patients with benign and borderline-malignant tumors. Conclusions: Adrenal LPA are a heterogeneous group of tumors, mostly composed of oncocytomas. Up to 1/3 of those tumors may have a borderline-malignant potential at histopathology.

Published
2024
Full Text
View/download PDF

22. Exploring risk factors for non-response to CAR T-cell therapy in large B-cell lymphoma: A binational multicenter project on potential predictors of outcome

Author

Voltin, C., additional, Winkelmann, M., additional, Farolfi, A., additional, Beckmann, L., additional, Kobe, C., additional, Borchmann, P., additional, Fanti, S., additional, Subklewe, M., additional, Drzezga, A., additional, Kunz, W. G., additional, Herrmann, K., additional, Reinhardt, H. C., additional, Seifert, R., additional, Albring, J. C., additional, Blumenberg, V., additional, von Tresckow, B., additional, Paccagnella, A., additional, Gödel, P., additional, Flossdorf, S., additional, and Hanoun, C., additional

Published
2023
Full Text
View/download PDF

25. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

Author

Gillessen, S., Omlin, A., Attard, G., de Bono, J.S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P.S., Sartor, O., Smith, M.R., Soule, H.R., Akaza, H., Beer, T.M., Beltran, H., Chinnaiyan, A.M., Daugaard, G., Davis, I.D., De Santis, M., Drake, C.G., Eeles, R.A., Fanti, S., Gleave, M.E., Heidenreich, A., Hussain, M., James, N.D., Lecouvet, F.E., Logothetis, C.J., Mastris, K., Nilsson, S., Oh, W.K., Olmos, D., Padhani, A.R., Parker, C., Rubin, M.A., Schalken, J.A., Scher, H.I., Sella, A., Shore, N.D., Small, E.J., Sternberg, C.N., Suzuki, H., Sweeney, C.J., Tannock, I.F., and Tombal, B.

Published
2015
Full Text
View/download PDF

27. Immunohistochemical PSMA expression and histology predictors in primary staging high-risk prostate cancer patients studied with PSMA PET/CT

Author

Bianchi, L., primary, Vetrone, L., additional, Mei, R., additional, Farolfi, A., additional, Giunchi, F., additional, De Giovanni, A., additional, Serani, F., additional, Costa, F., additional, Droghetti, M., additional, Pissavini, A., additional, Schiavina, R., additional, Brunocilla, E., additional, Castellucci, P., additional, and Fanti, S., additional

Published
2022
Full Text
View/download PDF

28. Does metastases-direct therapy guided by PSMA PET/CT really improve oncologic outcomes in oligorecurrent prostate cancer patients?

Author

Droghetti, M., primary, Bianchi, L., additional, Costa, F., additional, Piazza, P., additional, Balestrazzi, E., additional, Pissavini, A., additional, Chessa, F., additional, Ceci, F., additional, Mei, R., additional, Puliatti, S., additional, Larcher, A., additional, Gandaglia, G., additional, Mottrie, A., additional, Briganti, A., additional, Fanti, S., additional, Montorsi, F., additional, Schiavina, R., additional, and Brunocilla, E., additional

Published
2022
Full Text
View/download PDF

29. The impact of PSMA PET/CT on oncologic outcomes of patients with recurrent prostate cancer: The experience of 3 high-volume European centers

Author

Droghetti, M., primary, Bianchi, L., additional, Costa, F., additional, Pissavini, A., additional, Piazza, P., additional, Balestrazzi, E., additional, Chessa, F., additional, Ceci, F., additional, Mei, R., additional, Castellucci, P., additional, Puliatti, S., additional, Larcher, A., additional, Gandaglia, G., additional, Mottrie, A., additional, Briganti, A., additional, Fanti, S., additional, Montorsi, F., additional, Schiavina, R., additional, and Brunocilla, E., additional

Published
2022
Full Text
View/download PDF

30. The Maximum Standardized Uptake Value in Patients with Recurrent or Persistent Prostate Cancer after Radical Prostatectomy and PSMA-PET-Guided Salvage Radiotherapy – A Multicenter Retrospective Analysis

Author

Spohn, S.K.B., primary, Farolfi, A., additional, Schandeler, S., additional, Vogel, M.M., additional, Ruf, J., additional, Mix, M., additional, Kirste, S., additional, Ceci, F., additional, Fanti, S., additional, Lanzafame, H., additional, Gratzke, C., additional, Sigle, A., additional, Combs, S.E., additional, Bernhardt, D., additional, Gschwend, J.E., additional, Buchner, J.A., additional, Trapp, C., additional, Belka, C., additional, Bartenstein, P., additional, Eiber, M., additional, Nekolla, S., additional, Schiller, K., additional, Grosu, A., additional, Schmidt-Hegemann, N.S., additional, Zamboglou, C., additional, and Peeken, J.C., additional

Published
2022
Full Text
View/download PDF

31. The impact of PSMA PET/CT on oncologic outcomes of patients with recurrent prostate cancer: the experience of 3 high-volume european centers

Author

Costa, F., primary, Bianchi, L., additional, Pissavini, A., additional, Droghetti, M., additional, Piazza, P., additional, Balestrazzi, E., additional, Chessa, F., additional, Ceci, F., additional, Mei, R., additional, Farolfi, A., additional, Puliatti, S., additional, Larcher, A., additional, Gandaglia, G., additional, Mottrie, A., additional, Bianchi, A., additional, Fanti, S., additional, Montorsi, F., additional, Schiavina, R., additional, and Brunocilla, E., additional

Published
2022
Full Text
View/download PDF

32. Immunohistochemical PSMA expression and histology predictors in primary staging high-risk prostate cancer patients studied with PSMA PET/ CT: a psma expression investigation

Author

Vetrone, L., primary, Mei, R., additional, Farolfi, A., additional, Bianchi, L., additional, Giunchi, F., additional, De Giovanni, A., additional, Calderoni, L., additional, Serani, F., additional, Costa, F., additional, Pissavini, A., additional, Schiavina, R., additional, Brunocilla, E., additional, Castellucci, P., additional, and Fanti, S., additional

Published
2022
Full Text
View/download PDF

33. Reliability of 68Ga-PSMA PET/CT in assessing real nodal burden in men with cN1 disease: clinical implications for patient counselling and multi-modal treatments

Author

Sorce, G., primary, Mazzone, E., additional, Stabile, A., additional, Robesti, D., additional, Bravi, C.A., additional, Scuderi, S., additional, Leni, R., additional, Balestrazzi, E., additional, Fanti, S., additional, Farolfi, A., additional, Bianchi, L., additional, Schiavina, R., additional, Montorsi, F., additional, and Briganti, A., additional

Published
2022
Full Text
View/download PDF

34. Optimizing timing and indications for 68Ga-PSMA PET/CT in patients with biochemical recurrent prostate cancer after radical prostatectomy

Author

Cucchiara, V., primary, Mazzone, E., additional, Robesti, D., additional, Gandaglia, G., additional, Stabile, A., additional, Scuderi, S., additional, Leni, R., additional, Barletta, F., additional, Nocera, L., additional, Necchi, A., additional, Raggi, D., additional, Marandino, L., additional, Balestrazzi, E., additional, Fanti, S., additional, Farolfi, A., additional, Bianchi, L., additional, Schiavina, R., additional, Montorsi, F., additional, and Briganti, A., additional

Published
2022
Full Text
View/download PDF

35. Does metastases-direct therapy guided by PSMA PET/CT really improve oncologic outcomes in oligorecurrent prostate cancer patients?

Author

Bianchi, L., primary, Costa, F., additional, Pietro, P., additional, Balestrazzi, E., additional, Droghetti, M., additional, Pissavini, A., additional, Chessa, F., additional, Ceci, F., additional, Mei, R., additional, Farolfi, A., additional, Castellucci, P., additional, Puliatti, S., additional, Larcher, A., additional, Gandaglia, G., additional, Mottrie, A., additional, Briganti, A., additional, Fanti, S., additional, Montorsi, F., additional, Schiavina, R., additional, and Brunocilla, E., additional

Published
2022
Full Text
View/download PDF

36. When node-positive prostate cancer should be considered a systemic disease? assessing the prognostic role of preoperative 68Ga-PSMA PET/ CT results in patients with lymph node invasion at final pathology

Author

Robesti, D., primary, Mazzone, E., additional, Gandaglia, G., additional, Stabile, A., additional, Necchi, A., additional, Raggi, D., additional, Marandino, L., additional, Cirulli, G.O., additional, Scuderi, S., additional, Barletta, F., additional, De Angelis, M., additional, Balestrazzi, E., additional, Fanti, S., additional, Farolfi, A., additional, Bianchi, L., additional, Schiavina, R., additional, Montorsi, F., additional, and Briganti, A., additional

Published
2022
Full Text
View/download PDF

38. Metastasis-free survival and patterns of distant metastatic disease after PSMA-PET-guided salvage radiotherapy in recurrent or persistent prostate cancer after prostatectomy

Author

Zamboglou, C., Strouthos, I., Sahlmann, J., Farolfi, A., Serani, F., Medici, F., Cavallini, L., Morganti, A.G., Trapp, C., Koerber, S.A., Peeken, J.C., Vogel, M.M.E., Schiller, K., Combs, S.E., Eiber, M., Vrachimis, A., Ferentinos, K., Spohn, S.K.B., Kirste, S., Gratzke, C., Ruf, J., Grosu, A.-., Ceci, F., Fendler, W.P., Miksch, J., Kroeze, S., Guckenberger, M., Lanzafame, H., Fanti, S., Hruby, G., Wiegel, T., Emmett, L., Schmidt-Hegemann, N.S., and Henkenberens, C.

Subjects
Male, Prostatectomy, Salvage Therapy, Prostate, Prostatic Neoplasms, Androgen Antagonists, Gallium Radioisotopes, Neoplasm Recurrence, Local, Settore MED/36 - Diagnostica per Immagini e Radioterapia, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography, Humans, Neoplasm Recurrence, Local, Retrospective Studies
Published
2022

45. 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease

Author

Zamagni, E, Nanni, C, Gay, F, Pezzi, A, Patriarca, F, Bellò, M, Rambaldi, I, Tacchetti, P, Hillengass, J, Gamberi, B, Pantani, L, Magarotto, V, Versari, A, Offidani, M, Zannetti, B, Carobolante, F, Balma, M, Musto, P, Rensi, M, Mancuso, K, Dimitrakopoulou-Strauss, A, Chauviè, S, Rocchi, S, Fard, N, Marzocchi, G, Storto, G, Ghedini, P, Palumbo, A, Fanti, S, and Cavo, M

Published
2016
Full Text
View/download PDF

50. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Gillessen, S. Armstrong, A. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Bossi, A. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Chi, K.N. Clarke, C.S. Clarke, N. Davis, I.D. de Bono, J.S. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Ekeke, O.N. Evans, C.P. Fanti, S. Feng, F.Y. Fizazi, K. Frydenberg, M. George, D. Gleave, M. Halabi, S. Heinrich, D. Higano, C. Hofman, M.S. Hussain, M. James, N. Jones, R. Kanesvaran, R. Khauli, R.B. Klotz, L. Leibowitz, R. Logothetis, C. Maluf, F. Millman, R. Morgans, A.K. Morris, M.J. Mottet, N. Mrabti, H. Murphy, D.G. Murthy, V. Oh, W.K. Ost, P. O'Sullivan, J.M. Padhani, A.R. Parker, C. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Shore, N. Skoneczna, I. Small, E. Smith, M. Soule, H. Spratt, D.E. Sternberg, C.N. Suzuki, H. Sweeney, C. Sydes, M.R. Taplin, M.-E. Tilki, D. Tombal, B. Türkeri, L. Uemura, H. Uemura, H. van Oort, I. Yamoah, K. Ye, D. Zapatero, A. Omlin, A.

Subjects
education
Abstract

Background: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate Cancer Consensus Conference (APCCC) addressed some of these questions to supplement guidelines that are based on level 1 evidence. Objective: To present the voting results from APCCC 2021. Design, setting, and participants: The experts identified three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood. A panel of 86 international prostate cancer experts developed the programme and the consensus questions. Outcome measurements and statistical analysis: The panel voted publicly but anonymously on 107 pre-defined questions, which were developed by both voting and non-voting panel members prior to the conference following a modified Delphi process. Results and limitations: The voting reflected the opinions of panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results reported in the Supplementary material. Conclusions: These voting results from a panel of experts in advanced prostate cancer can help clinicians and patients to navigate controversial areas of management for which high-level evidence is scant. However, diagnostic and treatment decisions should always be individualised according to patient characteristics, such as the extent and location of disease, prior treatment(s), comorbidities, patient preferences, and treatment recommendations, and should also incorporate current and emerging clinical evidence and logistic and economic constraints. Enrolment in clinical trials should be strongly encouraged. Importantly, APCCC 2021 once again identified salient questions that merit evaluation in specifically designed trials. Patient summary: The Advanced Prostate Cancer Consensus Conference is a forum for discussing current diagnosis and treatment options for patients with advanced prostate cancer. An expert panel votes on predefined questions focused on the most clinically relevant areas for treatment of advanced prostate cancer for which there are gaps in knowledge. The voting results provide a practical guide to help clinicians in discussing treatment options with patients as part of shared decision-making. © 2022 The Author(s)

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results